6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of: March 2025

Commission file number: 001-36578

ENLIVEX THERAPEUTICS LTD.

(Translation of registrant’s name into English)

14 Einstein Street, Nes Ziona, Israel 7403618

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒        Form 40-F ☐

On March 4, 2025, Enlivex Therapeutics Ltd., a company organized under the laws of the State of Israel, issued a press release inviting investors to a webinar on March 5, 2025, at 11:00 a.m. ET to discuss the positive interim six-month data from the Phase I stage of its ongoing randomized, multi-country Phase I/II Allocetra™ trial in patients with moderate to severe knee osteoarthritis. A copy of such press release is furnished as Exhibit 99.1 to this Report on Form 6-K and incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: March 4, 2025

Exhibit 99.1

Enlivex Therapeutics Announces Investor Webinarto Discuss Positive Interim Data from Phase I/II Allocetra™ Trial in Knee Osteoarthritis

Ness-Ziona, Israel – March 4, 2025 – Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a live investor webinar on March 5, 2025, at 11:00 a.m. ET to discuss the positive interim six-month data from the Phase I stage of its ongoing randomized, multi-country Phase I/II Allocetra™ trial in patients with moderate to severe knee osteoarthritis.

The exclusive event, hosted by RedChip Companies, will feature the Company’s Chief Executive Officer, Oren Hershkovitz Ph.D., who will provide a detailed review of the interim results, which demonstrated a statistically significant 47.0% average reduction in reported pain (P=0.0001) and a 46% improvement in joint function at six months post-treatment. Additionally, 83% of treated patients were still considered responders to treatment at six months, which the Company believes highlights the durability and sustained efficacy of Allocetra™ as a potential breakthrough treatment for osteoarthritis. Importantly, no serious adverse events were reported, reinforcing the favorable safety profile of Allocetra™.

Dr. Hershkovitz commented, “We are excited by these promising interim results, which showcase Allocetra™’s potential to deliver meaningful and sustained, pain relief for patients suffering from moderate to severe knee osteoarthritis. The consistency and durability of the efficacy data—combined with the safety profile—underscore Allocetra™’s promising potential to become a novel treatment in a space with urgent unmet medical needs. We remain deeply committed to advancing this innovative therapy and unlocking its full potential for millions of patients worldwide.”

Webinar Details

• **Date:**March 5, 2025

• **Time:**11:00 a.m. ET

To register for the free webinar, please visit: https://redchip.zoom.us/webinar/register/WN_ZHfRf-8_R3etRq2e5iIPUg

A live Q&A session will follow the presentation. Questions can be pre-submitted to ENLV@redchip.com or online during the live event.

ABOUT ENLIVEX

Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit http://www.enlivex.com.

Safe Harbor Statement:  This press release contains forward-lookingstatements, which may be identified by words such as “expects,” “plans,” “projects,” “will,”“may,” “anticipates,” “believes,” “should,” “would”, “could,”“intends,” “estimates,” “suggests,” “has the potential to” and other words of similarmeaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinicalexperiments, the effectiveness of, and market opportunities for, ALLOCETRA ^TM^programs. All such forward-lookingstatements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Investors arecautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex’s business and prospects,including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that theproducts in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would supportthe approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continueto show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forthin the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the resultsof clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed,later-stage trials. The development of any products using the ALLOCETRA ^TM^product line could also be affected by anumber of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analysesand decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact ofpatents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above,investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex’s filingswith the Securities and Exchange Commission, including in the Company’s most recent Annual Report on Form 20-F filed with the Securitiesand Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statementswere made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.

Contact:

Dave Gentry, CEO

RedChip Companies, Inc.

1-407-644-4256

ENLV@redchip.com